You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Vibegron - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for vibegron and what is the scope of patent protection?

Vibegron is the generic ingredient in one branded drug marketed by Urovant and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vibegron has seventy-three patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for vibegron
International Patents:73
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 27
Clinical Trials: 11
Patent Applications: 66
What excipients (inactive ingredients) are in vibegron?vibegron excipients list
DailyMed Link:vibegron at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vibegron
Generic Entry Date for vibegron*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for vibegron

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Urovant Sciences GmbHPhase 2/Phase 3
Urovant Sciences GmbHPhase 4
Urovant Sciences GmbHPhase 2

See all vibegron clinical trials

Pharmacology for vibegron

US Patents and Regulatory Information for vibegron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Urovant GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Urovant GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Urovant GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Urovant GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for vibegron

Country Patent Number Title Estimated Expiration
Honduras 2010002030 HIDROXIMETIL PIRROLIDINAS COMO AGONISTAS DEL RECEPTOR ADRENERGICO BETA 3 ⤷  Sign Up
Chile 2019003533 Uso de vibegron para tratar vejiga sobreactiva. ⤷  Sign Up
Australia 2009231714 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists ⤷  Sign Up
Slovenia 2276756 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.